

UC San Diego

UC San Diego Previously Published Works

Title

Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A2 enzymes

Permalink

<https://escholarship.org/uc/item/48t63677>

Journal

Bioorganic & Medicinal Chemistry, 16(24)

ISSN

0968-0896

Authors

Antonopoulou, Georgia
Barbayianni, Efrosini
Magrioti, Victoria
[et al.](#)

Publication Date

2008-12-15

DOI

10.1016/j.bmc.2008.10.046

Peer reviewed

Published in final edited form as:

Bioorg Med Chem. 2008 December 15; 16(24): 10257–10269. doi:10.1016/j.bmc.2008.10.046.

Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A₂ enzymes

Georgia Antonopoulou^a, Efrosini Barbayianni^a, Victoria Magrioti^a, Naomi Cotton^b, Daren Stephens^b, Violetta Constantinou-Kokotou^c, Edward A. Dennis^{b,*}, and George Kokotos^{a,*}

^aLaboratory of Organic Chemistry, Department of Chemistry, University of Athens, Panepistimiopolis, Athens 15771, Greece

^bDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0601

^cChemical Laboratories, Agricultural University of Athens, Athens 11855, Greece

Abstract

A variety of 2-oxoamides and related amides based on natural and non-natural amino acids were synthesized. Their activity on two human intracellular phospholipases (GIVA cPLA₂ and GVIA iPLA₂) and one human secretory phospholipase (GV sPLA₂) was evaluated. We show that an amide based on (*R*)- γ -norleucine is a highly selective inhibitor of GV sPLA₂.

Keywords

Amides; Amino acids; Inhibitors; 2-Oxoamides; Phospholipase A₂

1. Introduction

The phospholipase A₂ (PLA₂) superfamily consists of a broad range of structurally distinct enzymes that catalyze the hydrolysis of the *sn*-2 ester bond of phospholipids. The PLA₂ superfamily has been systematically grouped based on the source (i.e. organism) and primary sequence.¹⁻³ In mammals, some of these enzymes are particularly interesting anti-inflammatory drug targets, in part due to their ability to liberate arachidonic acid for subsequent eicosanoid biosynthesis.¹⁻⁴ Specifically in human macrophages, three of these groups are known to play significant roles in immune response: cytosolic Ca²⁺-dependent PLA₂ (GIVA cPLA₂), cytosolic Ca²⁺-independent PLA₂ (GVIA iPLA₂) and Ca²⁺-dependent secretory PLA₂ (GV sPLA₂).

GIVA cPLA₂ is an attractive target for drug development since it is the rate-limiting provider of arachidonic acid and lysophospholipids that are subsequently converted into prostaglandins, leukotrienes and PAF, respectively.⁵ Various studies on transgenic mice lacking GIVA cPLA₂ showed a 90% reduction in the production of prostaglandins and leukotrienes.^{6,7} Recently, Kalyvas and David demonstrated that GIVA cPLA₂ plays an important role in the pathogenesis of experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis,⁸ while it was reported that cytosolic phospholipase A₂-deficient mice were resistant

*Corresponding authors. For G.K. phone: +30 210 727 4462; fax: +30 210 727 4761; gkokotos@chem.uoa.gr; For E.A.D.; phone: +1 858 534 3055; fax: +1 858 534 7390; edennis@ucsd.edu..

to experimental autoimmune encephalomyelitis.⁹ While the exact physiological roles remain in question, multiple studies confirm the primacy of GIVA cPLA₂ in lipid mediator production. Consequently, much effort has been focused on the design, synthesis and characterization of GIVA cPLA₂ inhibitors as potential agents for experimental exploration as well as treatment of various inflammatory conditions.

The role of the GVIA iPLA₂ in the inflammatory process is still unclear, and it has not been a target for the development of novel medicines up to now.¹⁰ This enzyme appears to be the primary PLA₂ for basal metabolic functions within the cell.

It has been shown that in macrophages and other cells, GIVA cPLA₂ and secretory phospholipase A₂ work together to release arachidonic acid.¹¹⁻¹⁵ Group GV sPLA₂ was identified at the DNA-level in humans,¹⁶ and subsequently expressed and characterized.¹⁷ Several experiments suggested that GV sPLA₂ has a role in amplifying the action of GIVA cPLA₂ in supplying arachidonic acid for eicosanoid production.¹⁸ In addition, GV sPLA₂ has cellular functions, independent of its ability to provide arachidonic acid, that include regulation of phagocytosis and foam cell formation.¹⁹ Thus, this enzyme was recently proposed to have a unique role in atherosclerosis.^{19b}

Kokotos and Magrioti recently reviewed many synthetic inhibitors of GIVA cPLA₂ and GVIA iPLA₂.²⁰ Since then, new *N*-benzylindole inhibitors²¹⁻²³ as well as 1-indol-1-yl-propan-2-ones²⁴ have been reported. Our recent efforts are focused on the development of a novel class of GIVA cPLA₂ inhibitors, initially designed to contain 2-oxoamide functionality and a free carboxyl group.²⁵⁻³² 2-Oxoamides based on γ -aminobutyric acid (**1a**; Figure 1) and the non-natural amino acids γ -norleucine or δ -norleucine (**1b** and **1c**; Figure 1) are potent inhibitors of GIVA cPLA₂ presenting *in-vivo* anti-inflammatory and analgesic activity.^{26,30} We have also demonstrated that ethyl 4-[(oxohexadecanoyl)amino]butanoate (**1d**; Figure 1) inhibits both GIVA cPLA₂ and GVIA iPLA₂ and is the first systemically bioavailable compound with a significant affinity for GIVA cPLA₂, which produces potent hyperalgesia.²⁸ *In-vivo*, intrathecal and systemic administration of inhibitor **1d** blocked carrageenan hyperalgesia.²⁸ Recently, a large number of lipophilic 2-oxoamides have been tested for inhibition of GV sPLA₂.³⁰ Only one compound (**2**, Figure 1) significantly inhibited GV sPLA₂ with an X_I(50) of 0.035 mole fraction. However, compound **2** inhibited both GIVA cPLA₂ and GVIA iPLA₂, in addition to GV sPLA₂, with no statistical preference.

Known inhibitors of secreted PLA₂ enzyme groups have been reviewed.³³ Among them, non-phospholipid amide inhibitors based on non-natural amino acids, such as compounds **3**³⁴ and **4**³⁵ (Figure 1), presented interesting inhibition of pancreatic and non-pancreatic GI and GII sPLA₂. Inhibitor **4** has been reported to protect rat small intestine from ischaemia and reperfusion injury³⁶ and trinitrobenzene sulfonic acid-induced colitis.³⁷

The selective inhibition of the each PLA₂ class is very important to understand enzyme-specific roles in cells and *in-vivo*. Therefore, we synthesized a variety of 2-oxoamide esters and related amides based on natural and non-natural amino acids and we evaluated their activity on GIVA cPLA₂, GV sPLA₂ and GVIA iPLA₂. While most of these compounds exhibited inhibitory properties for all three PLA₂ classes, we demonstrate that an amide based on (*R*)- γ -norleucine is a highly selective inhibitor of GV sPLA₂.

2. Results

2.1. Design and synthesis of inhibitors

Our previous work has shown that 2-oxoamides containing a free carboxyl group are selective inhibitors of GIVA cPLA₂, not affecting GVIA iPLA₂ and GV sPLA₂.^{26,29,30} On the contrary,

methyl or ethyl esters of 2-oxoamides may inhibit both GIVA cPLA₂ and GVIA iPLA₂.²⁹ In addition, the 2-oxoamide that contains a methyl ester group (**2**) inhibits all the three forms: GIVA cPLA₂, GVIA iPLA₂ and GV sPLA₂.³⁰ In this study, we decided to systematically evaluate: (a) the distance between the ester group and the 2-oxoamide functionality, and (b) the nature of the ester group. For structure-activity relationship (SAR) studies, we evaluated a variety of amino acid and ester substitutions such as glycine, β-alanine, γ-aminobutyric acid, δ-aminovaleric acid, and p-aminobenzoic acid as well as methyl, ethyl, and *tert*-butyl esters. The esters of amino acids **5a-l** were coupled with 2-hydroxy-hexadecanoic acid (**6**) using 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide as a condensing agent in the presence of 1-hydroxybenzotriazole (Scheme 1). The 2-hydroxyamides **7a-l** were oxidized to target compounds **8a-l** by treatment with Dess-Martin reagent.³⁸

Three 2-oxoamide esters based on γ-leucine, γ-norleucine and γ-alanine were prepared starting from the corresponding amino alcohols **9a-c** (Scheme 2) according to procedures we described previously.^{26,30} Oxidation by the NaOCl/AcNH-TEMPO method^{39,40} followed by Wittig reaction with methyl or *tert*-butyl (triphenylphosphoranylidene)acetate led to α,β-unsaturated esters **10a-c**. Oxidation of compounds **11a-c** by the Dess-Martin method produced the target compounds **12a-c**. To prepare 2-oxoamide esters based on ε-norleucine, Boc-L-norleucinol (**9b**) was oxidized to aldehyde and directly reacted with triethyl phosphonocrotonate⁴¹ (Scheme 3). Catalytic hydrogenation of compound **13**, removal of the Boc group by HCl/Et₂O and coupling with 2-hydroxy-hexadecanoic acid produced compound **16**. The unsaturated 2-hydroxyamide **15** was prepared by similar reaction. Both compounds **15** and **16** were oxidized to the corresponding 2-oxoamides **17** and **18** by the Dess-Martin method. 2-Oxoamide **19** containing a free carboxyl group was also prepared.

Ketone and ether analogues of the *in-vivo* active inhibitor **1d** were prepared as described in Scheme 4. Treatment of Boc-GABA with *n*-BuLi led to ketone **22** in moderate yield. Etherification of compound **21** under phase-transfer conditions produced ether **23**. Both compounds **22** and **23** were deprotected, coupled and oxidized to obtain the target derivatives **26** and **27**.

The known inhibitors **3** and **4** (Figure 1) of GI and GII sPLA₂ are amides consisting of a 7-phenylheptanoyl acyl residue and a non-natural γ-amino acid bearing a side chain with two aromatic groups. We decided to synthesize 2-oxoamides containing the 7-phenylheptanoyl residue instead of the long aliphatic chain. The synthesis procedure of 2-oxoamides **37a,b** and amides **32a,b**, based on methyl ester of glycine and *tert*-butyl ester of β-alanine, is depicted in Scheme 5.

In addition, we synthesized a γ-norleucine-based amide containing a 7-phenylheptanoyl chain. Boc-D-norleucinol (**38**), prepared according to the literature,^{42,43} was oxidized to aldehyde and treated with methyl or ethyl (phosphoranylidene)acetate to produce compounds **39a,b** (Scheme 6). After hydrogenation and removal of Boc group, coupling with 7-phenylheptanoic acid³⁵ gave amides **41a,b**. The target compound **42** was obtained after saponification of either **41a** or **41b**. Its enantiomer **43** was synthesized following similar reactions.

2.2. In vitro inhibition of GIVA cPLA₂, GVIA iPLA₂ and GV sPLA₂

Twenty six new derivatives including 2-oxoamides and amides were tested for inhibition of human GIVA cPLA₂, GVIA iPLA₂ and GV sPLA₂ using previously described mixed micelle-based assays.^{26,29,30} The relative degrees of inhibition are presented in Tables 1, 2 and 3 as either percent inhibition or X_I(50) values. Initially, the percent of inhibition for each PLA₂ enzyme at 0.091 mole fraction of each inhibitor was determined, and X_I(50) values were estimated for compounds that displayed greater than 90% inhibition. Each X_I(50) value is

derived from the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50%.

None of the methyl, ethyl or *tert*-butyl esters of 2-oxoamides based on glycine (**8a-c**), β -alanine (**8d-f**), and δ -aminovaleric acid (**8i-k**) (Table 1) display potent inhibition of GIVA cPLA₂ or GVIA iPLA₂. *Tert*-butyl esters (**8c**, **8f**, and **8k**) are better inhibitors than the corresponding methyl and ethyl esters. Allyl ester (**8g**) and benzyl ester (**8h**) analogues of inhibitor **1d** were found to be weak inhibitors of GIVA cPLA₂ and GVIA iPLA₂, indicating that the ethyl ester of GABA leads to better *in-vitro* results.²⁸

The esters of the 2-oxoamides based on γ -leucine (**12a**), γ -norleucine (**12b**) and γ -alanine (**12c**) are good inhibitors of GIVA cPLA₂ (Table 2). They also weakly inhibit GVIA iPLA₂. Derivative **8l** (Table 2) based on the aromatic amino acid seems to selectively inhibit GIVA cPLA₂, without affecting GVIA iPLA₂ activity. 2-Oxoamide ethyl esters based on ϵ -norleucine (saturated **18** or unsaturated **17**, Table 2) are weak inhibitors of both enzymes. It should be noticed that compound **19** (Table 2) containing a free carboxyl group is a selective inhibitor of GIVA cPLA₂, without affecting the activity of GVIA iPLA₂. This observation is in full agreement with our previous report that 2-oxoamides based on γ -amino acids are selective inhibitors of GIVA cPLA₂.^{29,30}

Among the 2-oxoamides based on esters of γ - and ϵ -amino acids, two derivatives (**12b** and **12c**, Table 2) based on esters of γ -norleucine and γ -alanine displayed inhibition of GV sPLA₂. However, compounds **12b** and **12c** also inhibited GIVA cPLA₂ and GVIA iPLA₂, and therefore demonstrated no statistical preference for the inhibition of the three enzymes.

To characterize the mode of interaction between the ethyl ester derivative **1d** and the active site of GIVA cPLA₂, we prepared two structurally related compounds, a ketone derivative **26** and an ether derivative **27**. In compound **26**, the carbonyl group is at the same position as in the ester derivative **1d**, although the alkoxy group was replaced by an alkyl group. In compound **27**, the ethoxy group of the ester derivative was kept constant, while the carbonyl group is absent. For synthetic reasons, we prepared a ketone derivative containing one additional carbon atom in the right chain of the ketone chain. However, this modification was not expected to play an essential role in inhibition. Neither compounds **26** or **27** presented interesting inhibitory properties, thereby confirming the essential inhibitory role of the ester group of compound **1d**.

Table 3 summarizes the *in-vitro* inhibition activities caused by 2-oxoamides and amides containing the 7-phenylheptanoyl chain instead of the long aliphatic chain. Comparing **37a** with **8a**, it seems that such a replacement of the long chain led to decreased activity for all the enzymes, as observed in the case of glycine methyl ester. However, similar activities were observed for **37b** and **8b**. The corresponding amides **32a** and **32b** were either totally inactive or very weak inhibitors. Interestingly, amide **42** based on (*R*)- γ -norleucine is a potent and selective GV sPLA₂ inhibitor, not affecting at all the activities of GIVA cPLA₂ and GVIA iPLA₂. The dose-response curve for the inhibition of GV sPLA₂ by amide **42** is shown in Figure 2, and a $X_1(50)$ value 0.003 ± 0.0004 was calculated. The configuration of the substituted amino acid is very important, since the amide **43** based on (*S*)- γ -norleucine was inactive for all the three PLA₂ enzymes.

3. Discussion

We previously demonstrated that 2-oxoamide **1d**, which is based on the ethyl ester of γ -aminobutyric acid, inhibits the GIVA cPLA₂ and GVIA iPLA₂ and exhibits very interesting antihyperalgesic activity.²⁸ The *tert*-butyl ester variant of compound **1d** (AX057) also inhibits both enzymes.²⁸ In addition, 2-oxoamides based on methyl esters of γ -aminobutyric acid or

α,β -unsaturated γ -norleucine are able to inhibit the same enzymes.²⁹ From the results of Table 1, we show that 2-oxoamide esters with varying distance between the 2-oxoamide functionality and the ester group (one to four carbon atoms) do not present any significant inhibition of GIVA cPLA₂ or GVIA iPLA₂. Interestingly, the introduction of a side-chain to the non-natural amino acids (Table 2) increases the potency of methyl or *tert*-butyl esters of γ -leucine, γ -norleucine, and γ -alanine (**12a-c**) for GIVA cPLA₂; but display rather weak inhibition of GVIA iPLA₂. Even so, increasing the spacer length to five carbon atoms, as seen in the ethyl ester of an ϵ -amino acid variant (**17**), leads to inhibition of both GIVA cPLA₂ and GVIA iPLA₂.

The 2-oxoamide compounds are inhibitors of various lipolytic enzymes (pancreatic and gastric lipases,⁴⁴⁻⁴⁸ GIVA cPLA₂,^{25,26,29,30} GVIA iPLA₂,²⁹) that utilize a serine residue as the nucleophile in their catalytic mechanism. In the cases of such serine esterases, it has been proposed that the serine hydroxyl group interacts with the activated carbonyl group of the 2-oxoamide functionality. The small, secreted human GV sPLA₂, as well as other sPLA₂ enzymes, utilizes a histidine residue in the catalytic site to coordinate a water molecule for hydrolysis at the *sn*-2 ester bond of phospholipids. It is likely that the long chain 2-oxoamides able to inhibit GV sPLA₂ resemble the transition state, explaining its high-affinity for the active site of GV sPLA₂.

We demonstrate that an amide based on a non-natural amino acid with a short linear aliphatic side chain (**42**) is a potent and selective inhibitor of GV sPLA₂. Comparing the present results with our previous studies, we conclude that a 2-oxoamide based on (*S*)- γ -norleucine, containing a long aliphatic chain, is a potent and selective inhibitor of GIVA cPLA₂,²⁶ while a simple amide based on (*R*)- γ -norleucine, containing a 7-phenylheptanoyl chain, is a potent and selective inhibitor of GV sPLA₂.

4. Conclusions

In conclusion, we synthesized a variety of 2-oxoamide and amides based on various amino acids and studied their activity on two human intracellular phospholipases (GIVA cPLA₂ and GVIA iPLA₂) and one human secretory phospholipase (GV sPLA₂). In summary, compounds with (*S*) configuration containing the 2-oxoamide functionality and a long fatty acyl chain provide selective inhibition of GIVA cPLA₂, while amide functionality in combination with the 7-phenylheptanoyl chain and the (*R*) configuration lead to selective inhibition of GV sPLA₂. Since both of these PLA₂s have been shown to contribute to the production of arachidonic acid, selective 2-oxoamide and amide inhibitors will be valuable tools for studies in cells and *in-vivo*.

5. Experimental Section

5.1. General procedures

Melting points were determined on a Buchi 530 apparatus and are uncorrected. Specific rotations were measured at 25 °C on a Perkin-Elmer 343 polarimeter using a 10 cm cell. NMR spectra were recorded on a Varian Mercury (200 Mz) spectrometer. Fast atom bombardment (FAB) mass spectra were recorded using a VG analytical ZAB-SE instrument. Electron spray ionization (ESI) mass spectra were recorded on a Finnigan, Surveyor MSQ Plus spectrometer. All amino acid derivatives were purchased from Fluka Chemical Co. TLC plates (silica gel 60 F₂₅₄) and silica gel 60 (70–230 or 230–400 mesh) for column chromatography were purchased from Merck. Visualization of spots was effected with UV light and/or phosphomolybdic acid and/or ninhydrin, both in EtOH stain. THF, toluene, and Et₂O were dried by standard procedures and stored over molecular sieves or Na. All other solvents and chemicals were reagent grade and used without further purification.

5.2. Synthesis of 2-Oxoamide Inhibitors

5.2.1. Coupling of 2-hydroxy-acids with amino components—To a stirred solution of 2-hydroxy-acid (1.0 mmol) and the amino component (1.0 mmol) in CH₂Cl₂ (10 mL), Et₃N (3.1 mL, 2.2 mmol) and subsequently 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (WSCl) (0.21 g, 1.1 mmol) and 1-hydroxybenzotriazole (HOBt) (0.14 g, 1.0 mmol) were added at 0 °C. The reaction mixture was stirred for 1 h at 0 °C and overnight at rt. The solvent was evaporated under reduced pressure and EtOAc (20 mL) was added. The organic layer was washed consecutively with brine, 1N HCl, brine, 5% NaHCO₃, and brine, dried over Na₂SO₄ and evaporated under reduced pressure. The residue was purified by column-chromatography using CHCl₃/MeOH as eluent.

5.2.1.1. Methyl 2-(2-hydroxyhexadecanamido)acetate (7a): Yield 82%; White solid; m.p. 116–118 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.02 (t, *J* = 4.8 Hz, 1H), 4.20–4.14 (m, 1H), 4.10–4.06 (m, 2H), 3.77 (s, 3H), 2.78 (br, 1H), 1.94–1.56 (m, 2H), 1.26 (br s, 24H), 0.89 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.2, 170.3, 72.2, 52.4, 40.8, 34.8, 31.9, 29.6, 29.5, 29.4, 29.3, 24.9, 22.7, 14.1. Anal. calcd for C₁₉H₃₇NO₄: C, 66.43; H, 10.86; N, 4.08. Found: C, 66.65; H, 10.71; N, 4.13.

5.2.1.2. Ethyl 2-(2-hydroxyhexadecanamido)acetate (7b): Yield 75%; White solid; m.p. 115–117 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.98 (m, 1H), 4.29–4.07 (m, 5H), 1.93–1.53 (m, 2H), 1.26 (br s, 27H), 0.89 (t, *J* = 5.8 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.2, 169.9, 72.2, 61.6, 40.9, 34.8, 31.9, 29.6, 29.5, 29.4, 29.3, 24.9, 22.7, 14.1. Anal. calcd for C₂₀H₃₉NO₄: C, 67.19; H, 10.99; N, 3.92. Found: C, 67.33; H, 10.83; N, 3.99.

5.2.1.3. tert-Butyl 2-(2-hydroxyhexadecanamido)acetate (7c): Yield 77%; White solid; m.p. 53–56 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.03 (t, *J* = 5.2 Hz, 1H), 4.18–4.12 (m, 1H), 3.99–3.93 (m, 2H), 3.15 (br, 1H), 1.89–1.50 (m, 2H), 1.47 (s, 9H), 1.25 (br s, 24H), 0.88 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.3, 169.1, 82.4, 72.2, 41.5, 34.7, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.0, 25.0, 22.7, 14.1. Anal. calcd for C₂₂H₄₃NO₄: C, 68.53; H, 11.24; N, 3.63. Found: C, 68.45; H, 11.37; N, 3.71.

5.2.1.4. Methyl 3-(2-hydroxyhexadecanamido)propanoate (7d): Yield 79%; White solid; m.p. 111–114 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.00 (br, 1H), 4.12–4.06 (m, 1H), 3.71 (s, 3H), 3.61–3.51 (m, 2H), 2.86 (br, 1H), 2.57 (t, *J* = 6 Hz, 2H), 1.86–1.55 (m, 2H), 1.25 (br s, 24H), 0.88 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.0, 172.9, 72.0, 51.9, 34.9, 34.5, 33.8, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 24.9, 22.7, 14.1. Anal. calcd for C₂₀H₃₉NO₄: C, 67.19; H, 10.99; N, 3.92. Found: C, 67.03; H, 11.21; N, 3.86.

5.2.1.5. Ethyl 3-(2-hydroxyhexadecanamido)propanoate (7e): Yield 68%; White solid; m.p. 102–104 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.07 (t, *J* = 6 Hz, 1H), 4.15 (q, *J* = 7.2 Hz, 2H), 4.09–4.04 (m, 1H), 3.59–3.49 (m, 2H), 3.20 (br, 1H), 2.54 (t, *J* = 6.2 Hz, 2H), 1.86–1.50 (m, 2H), 1.24 (br s, 27H), 0.87 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.1, 172.4, 72.0, 60.8, 34.8, 34.5, 34.0, 31.9, 29.6, 29.5, 29.4, 29.3, 24.9, 22.6, 14.1, 14.0. Anal. calcd for C₂₁H₄₁NO₄: C, 67.88; H, 11.12; N, 3.77. Found: C, 67.64; H, 11.34; N, 3.71.

5.2.1.6. tert-Butyl 3-(2-hydroxyhexadecanamido)propanoate (7f): Yield 63%; White solid; m.p. 95–97 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.97 (t, *J* = 5.8 Hz, 1H), 4.11–4.05 (m, 1H), 3.56–3.46 (m, 2H), 2.83 (br, 1H), 2.44 (t, *J* = 5.8 Hz, 2H), 1.88–1.51 (m, 2H), 1.44 (s, 9H), 1.23 (br s, 24H), 0.86 (t, *J* = 6.6 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 173.8, 171.7, 81.2, 72.0, 35.1, 35.0, 34.7, 31.9, 29.6, 29.5, 29.4, 29.3, 28.1, 24.8, 22.7, 14.1. Anal. calcd for C₂₃H₄₅NO₄: C, 69.13; H, 11.35; N, 3.51. Found: C, 69.01; H, 11.48; N, 3.44.

5.2.1.7. Benzyl 4-(2-hydroxyhexadecanamido)butanoate (7g): Yield 64%; White solid; m.p. 89-91 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.36 (m, 5H), 6.72 (t, *J* = 5.8 Hz, 1H), 5.13 (s, 2H), 4.09-4.03 (m, 1H), 3.37-3.28 (m, 2H), 2.85 (br, 1H), 2.42 (t, *J* = 7 Hz, 2H), 1.95-1.50 (m, 4H), 1.26 (br s, 24H), 0.88 (t, *J* = 6.6 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.1, 173.1, 135.7, 128.6, 128.3, 128.2, 72.1, 66.4, 38.4, 34.9, 31.9, 31.6, 29.7, 29.62, 29.58, 29.5, 29.4, 29.3, 25.0, 24.6, 22.7, 14.1. Anal. calcd for C₂₇H₄₅NO₄: C, 72.44; H, 10.13; N, 3.13. Found: C, 72.61; H, 9.95; N, 3.23.

5.2.1.8. Allyl 4-(2-hydroxyhexadecanamido)butanoate (7h): Yield 71%; White solid; m.p. 91-93 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.71 (t, *J* = 5.4 Hz, 1H), 6.02-5.82 (m, 1H), 5.36-5.22 (m, 2H), 4.61-4.57 (m, 2H), 4.12-4.06 (m, 1H), 3.39-3.29 (m, 2H), 2.59 (br, 1H), 2.40 (t, *J* = 7.2 Hz, 2H), 1.95-1.52 (m, 4H), 1.25 (br s, 24H), 0.88 (t, *J* = 6.6 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.0, 173.0, 132.0, 118.4, 72.1, 65.3, 38.5, 34.9, 31.9, 31.6, 29.7, 29.6, 29.5, 29.4, 29.3, 25.0, 24.6, 22.7, 14.1. Anal. calcd for C₂₃H₄₃NO₄: C, 69.48; H, 10.90; N, 3.52. Found: C, 69.62; H, 10.75; N, 3.57.

5.2.1.9. Methyl 5-(2-hydroxyhexadecanamido)pentanoate (7i): Yield 66%; White solid; m.p. 105-107 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.73 (t, *J* = 5.8 Hz, 1H), 4.10-4.04 (m, 1H), 3.66 (s, 3H), 3.32-3.22 (m, 2H), 3.17 (br, 1H), 2.34 (t, *J* = 7 Hz, 2H), 1.79-1.51 (m, 6H), 1.24 (br s, 24H), 0.87 (t, *J* = 7 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.2, 174.0, 72.1, 51.6, 38.5, 34.9, 33.4, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.9, 25.0, 22.6, 22.0, 14.1. Anal. calcd for C₂₂H₄₃NO₄: C, 68.53; H, 11.24; N, 3.63. Found: C, 68.77; H, 11.13; N, 3.58.

5.2.1.10. Ethyl 5-(2-hydroxyhexadecanamido)pentanoate (7j): Yield 68%; White solid; m.p. 95-97 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.69 (t, *J* = 5.8 Hz, 1H), 4.17-4.06 (m, 3H), 3.33-3.23 (m, 2H), 3.15 (br, 1H), 2.33 (t, *J* = 7 Hz, 2H), 1.79-1.58 (m, 6H), 1.24 (br s, 27H), 0.87 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.0, 173.5, 72.1, 60.4, 38.5, 34.9, 33.7, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.9, 25.0, 22.7, 22.0, 14.1. Anal. calcd for C₂₃H₄₅NO₄: C, 69.13; H, 11.35; N, 3.51. Found: C, 68.97; H, 11.59; N, 3.43.

5.2.1.11. *tert*-Butyl 5-(2-hydroxyhexadecanamido)pentanoate (7k): Yield 61%; White solid; m.p. 60-63 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.71 (t, *J* = 5.6 Hz, 1H), 4.11-4.06 (m, 1H), 3.32-3.23 (m, 2H), 2.24 (t, *J* = 7 Hz, 2H), 1.81-1.46 (m, 6H), 1.43 (s, 9H), 1.23 (br s, 24H), 0.87 (t, *J* = 6.6 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.1, 173.0, 80.4, 72.1, 38.6, 34.9, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.9, 28.0, 25.0, 22.7, 22.1, 14.1. Anal. calcd for C₂₅H₄₉NO₄: C, 70.21; H, 11.55; N, 3.28. Found: C, 70.02; H, 11.68; N, 3.32.

5.2.1.12. Ethyl 4-(2-hydroxyhexadecanamido)benzoate (7l): Yield 43%; Oily solid; ¹H NMR (200 MHz, CDCl₃) δ 8.74 (s, 1H), 8.06 (s, 1H), 7.95-7.33 (m, 3H), 4.37 (q, *J* = 7 Hz, 2H), 4.28-4.22 (m, 1H), 3.35 (br, 1H), 1.90-1.61 (m, 2H), 1.25 (br s, 27H), 0.88 (t, *J* = 5.8 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 172.7, 166.3, 137.5, 131.1, 129.1, 125.4, 124.1, 120.6, 72.6, 61.2, 34.7, 31.9, 29.7, 29.5, 29.4, 29.3, 25.0, 22.6, 14.2, 14.1. Anal. calcd for C₂₅H₄₁NO₄: C, 71.56; H, 9.85; N, 3.34. Found: C, 71.33; H, 9.97; N, 3.42.

5.2.1.13. (4*R*)-Methyl 4-(2-hydroxyhexadecanamido)-6-methylheptanoate (11a): Yield 57%; White solid; ¹H NMR (200 MHz, CDCl₃) δ 6.40-6.20 (m, 1H), 4.20-3.90 (m, 2H), 3.66 (s, 3H), 3.10-2.90 (m, 1H), 2.35 (t, *J* = 7.8 Hz, 2H), 1.95- 1.47 (m, 5H), 1.40-1.18 (m, 26H), 0.95-0.81 (m, 9H). Anal. calcd for C₂₅H₄₉NO₄: C, 70.21; H, 11.55; N, 3.28. Found: C, 70.34; H, 11.46; N, 3.22.

5.2.1.14. (4*S*)-Methyl 4-(2-hydroxyhexadecanamido)octanoate (11b): Yield 62%; White solid; ¹H NMR (200 MHz, CDCl₃) δ 6.35-6.15 (m, 1H), 4.15-4.00 (m, 1H), 4.00-3.80 (m, 1H), 3.67 (s, 3H), 2.80-2.70 (m, 1H), 2.35 (t, *J* = 7.8 Hz, 2H), 1.97-1.42 (m, 6H), 1.38-1.15 (m,

28H), 0.98-0.81 (m, 6H). Anal. calcd for C₂₅H₄₉NO₄: C, 70.21; H, 11.55; N, 3.28. Found: C, 70.04; H, 11.62; N, 3.36.

5.2.1.15. (4S)-tert-Butyl 4-(2-hydroxyhexadecanamido)pentanoate (11c): Yield 58%; White solid; ¹H NMR (200 MHz, CDCl₃) δ 6.60-6.40 (m, 1H), 4.10-3.90 (m, 2H), 3.15-2.95 (m, 1H), 2.27 (t, *J* = 7.8 Hz, 2H), 1.98-1.52 (m, 4H), 1.44 (s, 9H), 1.40-1.21 (m, 24H), 1.16 (d, *J* = 6.6 Hz, 3H), 0.88 (t, *J* = 6.6 Hz, 3H). Anal. calcd for C₂₅H₄₉NO₄: C, 70.21; H, 11.55; N, 3.28. Found: C, 70.05; H, 11.74; N, 3.21.

5.2.1.16. (2E,4E,6S)-Ethyl 6-(2-hydroxyhexadecanamido)deca-2,4-dienoate (15): Yield 58%; Waxy solid; ¹H NMR (200 MHz, CDCl₃) δ 7.35 (dd, *J*₁ = 15.6 Hz, *J*₂ = 10.8 Hz, 1H), 6.73-6.67 (m, 1H), 6.26 (dd, *J*₁ = 15.2 Hz, *J*₂ = 11 Hz, 1H), 6.12 (dd, *J*₁ = 15 Hz, *J*₂ = 5.8 Hz, 1H), 5.95 (d, *J* = 15.4 Hz, 1H), 4.73-4.57 (m, 1H), 4.35-4.24 (m, 3H), 3.11 (d, *J* = 4.8 Hz, 2/3H), 3.03 (d, *J* = 4.8 Hz, 1/3H), 1.92-1.58 (m, 4H), 1.29 (br s, 31H), 0.89 (t, *J* = 6.6 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 173.2, 167.0, 143.7, 142.5, 128.0, 121.5, 72.2, 60.4, 50.1, 34.9, 34.5, 31.9, 29.7, 29.6, 29.4, 29.3, 27.8, 24.9, 22.7, 22.4, 14.2, 14.1, 13.9. Anal. calcd for C₂₈H₅₁NO₄: C, 72.21; H, 11.04; N, 3.01. Found: C, 72.34; H, 10.97; N, 2.97.

5.2.1.17. (6S)-Ethyl 6-(2-hydroxyhexadecanamido)decanoate (16): Yield 55%; White solid; ¹H NMR (200 MHz, CDCl₃) δ 6.28-6.18 (m, 1H), 4.16-4.06 (m, 3H), 3.92-3.89 (m, 1H), 3.11 (d, *J* = 4.4 Hz, 2/3H), 2.94 (d, *J* = 5 Hz, 1/3H), 2.28 (t, *J* = 7.4 Hz, 2H), 1.93-1.21 (m, 41H), 0.88 (t, *J* = 6.6 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 173.9, 173.5, 72.2 (72.0), 60.3, 48.6 (48.8), 35.1, 34.9, 34.8, 34.7, 34.1, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 28.0, 25.4, 25.3, 24.9, 24.8, 24.7, 22.7 (22.6), 14.2, 14.1, 14.0. Anal. calcd for C₂₈H₅₅NO₄: C, 71.59; H, 11.80; N, 2.98. Found: C, 71.28; H, 11.95; N, 2.94.

5.2.1.18. 2-Hydroxy-N-(4-oxooctyl)hexadecanamide (24): Yield 70%; White solid; m.p. 122-124 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.73 (t, *J* = 5.8 Hz, 1H), 4.22-4.06 (m, 1H), 3.34-3.28 (m, 2H), 2.56-2.40 (m, 4H), 1.97-1.73 (m, 3H), 1.73-1.20 (m, 30H), 0.88 (t, *J* = 6.6 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 211.2, 174.0, 72.1, 42.7, 40.0, 38.7, 34.9, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 25.9, 25.0, 23.3, 22.7, 22.3, 14.1, 13.8. Anal. calcd for C₂₄H₄₇NO₃: C, 72.49; H, 11.91; N, 3.52. Found: C, 72.38; H, 11.99; N, 3.56.

5.2.1.19. N-(4-Ethoxybutyl)-2-hydroxyhexadecanamide (25): Yield 67%; White solid; m.p. 92-95 °C; ¹H NMR (200 MHz, CDCl₃) δ 6.75 (t, *J* = 5.8 Hz, 1H), 4.10-4.02 (m, 1H), 3.52-3.26 (m, 7H), 1.95-1.50 (m, 6H), 1.25 (br s, 27H), 0.87 (t, *J* = 6.6 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 174.1, 72.0, 70.1, 66.2, 38.8, 35.0, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 27.1, 26.4, 25.0, 22.6, 15.1, 14.1. Anal. calcd for C₂₂H₄₅NO₃: C, 71.11; H, 12.21; N, 3.77. Found: C, 71.24; H, 12.15; N, 3.72.

5.2.1.20. Methyl 2-(7-phenylheptanamido)acetate (32a): Yield 45%; White solid; m.p. 48-50 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.40-7.21 (m, 5H), 6.30 (b, 1H), 4.11 (d, *J* = 5.6 Hz, 2H), 3.83 (s, 3H), 2.69 (t, *J* = 7.2 Hz, 2H), 2.32 (t, *J* = 7.4 Hz, 2H), 1.81-1.62 (m, 4H), 1.55-1.38 (m, 4H); ¹³C NMR (50 MHz, CDCl₃) δ 173.3, 170.4, 142.5, 128.2, 128.1, 125.5, 52.1, 41.0, 36.1, 35.7, 31.1, 28.9, 28.8, 25.3; MS (ESI) *m/z*(%): 278 (100) [M+H]⁺; Anal. calcd for C₁₆H₂₃NO₃: C, 69.29; H, 8.36; N, 5.05. Found: C, 68.92; H, 8.47; N, 5.11.

5.2.1.21. tert-Butyl 3-(7-phenylheptanamido)propanoate (32b): Yield 45%; Oil; ¹H NMR (200 MHz, CDCl₃) δ 7.40-7.23 (m, 5H), 6.18 (br s, 1H), 3.56 (q, 2H), 2.68 (t, *J* = 7.4 Hz, 2H), 2.53 (t, *J* = 6.2 Hz, 2H), 2.23 (t, *J* = 7.0 Hz, 2H), 1.80-1.62 (m, 4H), 1.54 (s, 9H), 1.51-1.38 (m, 4H); ¹³C NMR (50 MHz, CDCl₃) δ 173.0, 172.2, 142.6, 128.3, 128.2, 125.5, 81.0, 36.7, 35.8, 35.0, 34.8, 31.2, 29.0, 28.9, 28.0, 25.6; MS (ESI) *m/z*(%): 356 (100) [M+Na]⁺; Anal. calcd for C₂₀H₃₁NO₃: C, 72.04; H, 9.37; N, 4.20. Found: C, 71.76; H, 9.59; N, 4.36.

5.2.1.22. Methyl 2-(2-hydroxy-8-phenyloctanamido)acetate (36a): Yield 41%; White solid; m.p. 65-67 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.39-7.25 (m, 6H), 4.27-4.08 (m, 3H), 3.83 (s, 3H), 3.32 (br s, 1H), 2.68 (t, $J = 7.4$ Hz, 2H), 1.98-1.62 (m, 4H), 1.58-1.35 (m, 6H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 174.7, 170.4, 142.7, 128.3, 128.2, 125.5, 72.1, 52.3, 40.7, 35.8, 34.6, 31.3, 29.2, 29.1, 24.8; Anal. calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_4$: C, 66.43; H, 8.20; N, 4.56. Found: C, 66.29; H, 8.11; N, 4.61.

5.2.1.23. *tert*-Butyl 3-(2-hydroxy-8-phenyloctanamido)propanoate (36b): Yield 32%; White solid; m.p. 62-64 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.40-7.23 (m, 5H), 7.13 (t, $J = 5.8$ Hz, 1H), 4.16 (dd, $J_1 = 3.6$ Hz, $J_2 = 7.2$ Hz, 1H), 3.59 (q, $J = 6.4$ Hz, 2H), 3.10 (br s, 1H), 2.68 (t, $J = 7.4$ Hz, 2H), 2.54 (t, $J = 6.2$ Hz, 2H), 1.95-1.78 (m, 1H), 1.76-1.61 (m, 3H), 1.54 (s, 9H), 1.42-1.35 (m, 6H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 174.0, 171.7, 142.7, 128.3, 128.2, 125.5, 81.2, 71.9, 35.9, 35.2, 34.8, 34.7, 31.4, 29.2, 29.1, 28.0, 24.8; Anal. calcd for $\text{C}_{21}\text{H}_{33}\text{NO}_4$: C, 69.39; H, 9.15; N, 3.85. Found: C, 69.28; H, 9.21; N, 3.94.

5.2.1.24. (*R*)-Ethyl 4-(7-phenylheptanamido)octanoate (41a): Yield 89%; White solid; m.p. 54-56 °C; $[\alpha]_{\text{D}} = +8.2$ (c 1 CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.39-7.23 (m, 5H), 5.88 (d, $J = 9.0$ Hz, 1H), 4.19 (q, $J = 7.0$ Hz, 2H), 4.03 (br s, 1H), 2.69 (t, $J = 7.4$ Hz, 2H), 2.43 (t, $J = 7.6$ Hz, 2H), 2.24 (t, $J = 6.8$ Hz, 2H), 1.99-1.87 (m, 2H), 1.83-1.60 (m, 6H), 1.56-1.36 (m, 8H), 1.32 (t, $J = 7.4$ Hz, 3H), 0.98 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 173.5, 172.6, 142.4, 128.1, 128.0, 125.4, 60.2, 48.5, 36.6, 35.6, 34.8, 31.1, 30.9, 29.8, 28.9, 28.8, 27.8, 25.6, 22.3, 14.0, 13.9; MS (ESI) m/z (%): 398 (100) $[\text{M}+\text{Na}]^+$; Anal. calcd for $\text{C}_{23}\text{H}_{37}\text{NO}_3$: C, 73.56; H, 9.93; N, 3.73. Found: C, 73.22; H, 10.18; N, 3.79.

5.2.1.25. (*R*)-Methyl 4-(7-phenylheptanamido)octanoate (41b): Yield 70%; White solid; m.p. 62-64 °C; $[\alpha]_{\text{D}} = +9.3$ (c 1 CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.40-7.23 (m, 5H), 5.45 (d, $J = 8.2$ Hz, 1H), 4.12-3.95 (m, 1H), 3.74 (s, 3H), 2.69 (t, $J = 7.0$ Hz, 2H), 2.43 (t, $J = 7.4$ Hz, 2H), 2.23 (t, $J = 7.4$ Hz, 2H), 2.05-1.85 (m, 1H), 1.79-1.60 (m, 5H), 1.55-1.36 (m, 10H), 0.97 (t, $J = 6.2$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 174.2, 172.7, 142.6, 128.3, 128.2, 125.5, 51.6, 48.8, 36.8, 35.8, 31.2, 30.8, 30.0, 29.1, 28.9, 28.0, 25.7, 22.5, 13.9; Anal. calcd for $\text{C}_{22}\text{H}_{35}\text{NO}_3$: C, 73.09; H, 9.76; N, 3.87. Found: C, 72.77; H, 9.97; N, 3.95.

5.2.2. Oxidation of 2-hydroxy-amides—To a solution of 2-hydroxy-amide (1 mmol) in dry CH_2Cl_2 (10 mL) Dess-Martin periodinane was added (0.64 g, 1.5 mmol) and the mixture was stirred for 1 h at rt. The organic solution was washed with 10% aqueous NaHCO_3 , dried over Na_2SO_4 and the organic solvent was evaporated under reduced pressure. The residue was purified by column-chromatography using CHCl_3 as eluent.

5.2.2.1. Methyl 2-(2-oxohexadecanamido)acetate (8a): Yield 91%; White solid; m.p. 79-81 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.42-7.36 (m, 1H), 4.09 (d, $J = 5.8$ Hz, 2H), 3.79 (s, 3H), 2.91 (t, $J = 7.8$ Hz, 2H), 1.68-1.52 (m, 2H), 1.25 (br s, 22H), 0.88 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 198.2, 169.3, 160.2, 52.5, 40.9, 36.7, 31.9, 29.62, 29.56, 29.4, 29.33, 29.30, 29.0, 23.1, 22.7, 14.1; MS (ESI): m/z (%): 364 (51) $[\text{M} + \text{Na}]^+$; Anal. calcd for $\text{C}_{19}\text{H}_{35}\text{NO}_4$: C, 66.83; H, 10.33; N, 4.10. Found: C, 66.92; H, 10.25; N, 4.04.

5.2.2.2. Ethyl 2-(2-oxohexadecanamido)acetate (8b): Yield 84%; White solid; m.p. 66-68 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.10-6.91 (m, 1H), 4.22 (q, $J = 7$ Hz, 2H), 4.07 (d, $J = 5.4$ Hz, 2H), 2.90 (t, $J = 7.2$ Hz, 2H), 1.89-1.56 (m, 4H), 1.53-1.08 (br s, 23H), 0.86 (t, $J = 7$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 198.2, 168.8, 160.2, 61.7, 41.0, 36.7, 31.9, 29.6, 29.5, 29.4, 29.30, 29.26, 29.0, 23.1, 22.6, 14.1; MS (ESI): m/z (%): 378 (100) $[\text{M} + \text{Na}]^+$, 356 (5) $[\text{M} + \text{H}]^+$; Anal. calcd for $\text{C}_{20}\text{H}_{37}\text{NO}_4$: C, 67.57; H, 10.49; N, 3.94. Found: C, 67.71; H, 10.42; N, 3.89.

5.2.2.3. *tert*-Butyl 2-(2-oxohexadecanamido)acetate (8c): Yield 81%; White solid; m.p. 54-56 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.43-7.32 (m, 1H), 3.97 (d, $J = 5.6$ Hz, 2H), 2.91 (t, $J = 7.4$ Hz, 2H), 1.65-1.52 (m, 2H), 1.48 (s, 9H), 1.25 (br s, 22H), 0.88 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 198.3, 167.9, 160.1, 82.7, 41.7, 36.7, 31.9, 29.63, 29.57, 29.4, 29.34, 29.30, 29.0, 28.0, 23.1, 22.7, 14.1; MS (ESI): m/z (%): 406 (78) $[\text{M} + \text{Na}]^+$; Anal. calcd for $\text{C}_{22}\text{H}_{41}\text{NO}_4$: C, 68.89; H, 10.77; N, 3.65. Found: C, 68.95; H, 10.69; N, 3.72.

5.2.2.4. Methyl 3-(2-oxohexadecanamido)propanoate (8d): Yield 74%; White solid; m.p. 83-86 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.45-7.33 (m, 1H), 3.71 (s, 3H), 3.62-3.53 (m, 2H), 2.89 (t, $J = 6.6$ Hz, 2H), 2.58 (t, $J = 6.2$ Hz, 2H), 1.62-1.52 (m, 2H), 1.25 (br s, 22H), 0.88 (t, $J = 7$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 198.9, 172.2, 160.2, 51.9, 36.7, 34.7, 33.5, 31.9, 29.61, 29.56, 29.4, 29.30, 29.32, 29.0, 23.1, 22.7, 14.1; MS (ESI): m/z (%): 378 (100) $[\text{M} + \text{Na}]^+$, 356 (9) $[\text{M} + \text{H}]^+$; Anal. calcd for $\text{C}_{20}\text{H}_{37}\text{NO}_4$: C, 67.57; H, 10.49; N, 3.94. Found: C, 67.46; H, 10.53; N, 3.98.

5.2.2.5. Ethyl 3-(2-oxohexadecanamido)propanoate (8e): Yield 83%; White solid; m.p. 60-62 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.42 (t, $J = 6.2$ Hz, 1H), 4.16 (q, $J = 7.2$ Hz, 2H), 3.61-3.72 (m, 2H), 2.89 (t, $J = 7.4$ Hz, 2H), 2.56 (t, $J = 6.2$ Hz, 2H), 1.78-1.18 (m, 27H), 0.87 (t, $J = 6.4$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 198.9, 171.8, 160.1, 60.9, 36.7, 34.7, 33.7, 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 23.1, 22.7, 14.1; MS (FAB): m/z (%): 370 (100) $[\text{M} + \text{H}]^+$; Anal. calcd for $\text{C}_{21}\text{H}_{39}\text{NO}_4$: C, 68.25; H, 10.64; N, 3.79. Found: C, 68.17; H, 10.61; N, 3.84.

5.2.2.6. *tert*-Butyl 3-(2-oxohexadecanamido)propanoate (8f): Yield 75%; White solid; m.p. 44-45 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.43 (t, $J = 6.2$ Hz, 1H), 3.57-3.48 (m, 2H), 2.90 (t, $J = 7.4$ Hz, 2H), 2.47 (t, $J = 5.8$ Hz, 2H), 1.62-1.55 (m, 2H), 1.45 (s, 9H), 1.24 (br s, 22H), 0.87 (t, $J = 7$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.0, 171.0, 160.0, 81.4, 36.7, 34.8, 31.9, 29.61, 29.55, 29.4, 29.3, 29.0, 28.0, 23.1, 22.7, 14.1; MS (ESI): m/z (%): 420 (100) $[\text{M} + \text{Na}]^+$; Anal. calcd for $\text{C}_{23}\text{H}_{43}\text{NO}_4$: C, 69.48; H, 10.90; N, 3.52. Found: C, 69.41; H, 10.84; N, 3.62.

5.2.2.7. Benzyl 4-(2-oxohexadecanamido)butanoate (8g): Yield 91%; White solid; m.p. 68-70 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.42-7.29 (m, 5H), 7.11 (t, $J = 5.8$ Hz, 1H), 5.13 (s, 2H), 3.40-3.30 (m, 2H), 2.90 (t, $J = 7.4$ Hz, 2H), 2.42 (t, $J = 7.2$ Hz, 2H), 1.98-1.84 (m, 2H), 1.68-1.53 (m, 2H), 1.26 (br s, 22H), 0.89 (t, $J = 6.2$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.2, 172.7, 160.3, 135.7, 128.6, 128.31, 128.25, 66.5, 38.6, 36.7, 31.9, 31.5, 29.6, 29.5, 29.4, 29.3, 29.0, 24.4, 23.1, 22.7, 14.1; MS (ESI): m/z (%): 468 (100) $[\text{M} + \text{Na}]^+$; Anal. calcd for $\text{C}_{27}\text{H}_{43}\text{NO}_4$: C, 72.77; H, 9.73; N, 3.14. Found: C, 72.86; H, 9.57; N, 3.23.

5.2.2.8. Allyl 4-(2-oxohexadecanamido)butanoate (8h): Yield 83%; White solid; m.p. 60-62 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.10 (t, $J = 6.2$ Hz, 1H), 6.02-5.82 (m, 1H), 5.37-5.22 (m, 2H), 4.61-4.58 (m, 2H), 3.41-3.31 (m, 2H), 2.91 (t, $J = 7.6$ Hz, 2H), 2.40 (t, $J = 7.2$ Hz, 2H), 2.05-1.84 (m, 2H), 1.64-1.56 (m, 2H), 1.26 (br s, 22H), 0.88 (t, $J = 6.8$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.2, 172.5, 160.3, 132.0, 118.5, 65.3, 38.6, 36.7, 31.9, 31.5, 29.6, 29.5, 29.4, 29.3, 29.0, 24.4, 23.2, 22.7, 14.1; MS (ESI): m/z (%): 418 (100) $[\text{M} + \text{Na}]^+$; Anal. calcd for $\text{C}_{23}\text{H}_{41}\text{NO}_4$: C, 69.83; H, 10.45; N, 3.54. Found: C, 69.72; H, 10.52; N, 3.47.

5.2.2.9. Methyl 5-(2-oxohexadecanamido)pentanoate (8i): Yield 93%; White solid; m.p. 68-70 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.03 (t, $J = 6.2$ Hz, 1H), 3.68 (s, 3H), 3.36-3.27 (m, 2H), 2.91 (t, $J = 7.2$ Hz, 2H), 2.35 (t, $J = 6.6$ Hz, 2H), 1.70-1.56 (m, 6H), 1.25 (br s, 22H), 0.88 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.3, 173.7, 160.2, 51.6, 38.8, 36.7, 33.4, 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 28.6, 23.1, 22.7, 22.0, 14.1; MS (ESI): m/z (%): 406 (100) $[\text{M} + \text{Na}]^+$; Anal. calcd for $\text{C}_{22}\text{H}_{41}\text{NO}_4$: C, 68.89; H, 10.77; N, 3.65. Found: C, 68.97; H, 10.71; N, 3.62.

5.2.2.10. Ethyl 5-(2-oxohexadecanamido)pentanoate (8j): Yield 87%; White solid; m.p. 59-61 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.03 (t, $J = 6.2$ Hz, 1H), 4.13 (q, $J = 7.2$ Hz, 2H), 3.36-3.26 (m, 2H), 2.91 (t, $J = 7.4$ Hz, 2H), 2.33 (t, $J = 7$ Hz, 2H), 1.75-1.56 (m, 6H), 1.25 (m, 25H), 0.88 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.3, 173.3, 160.2, 60.4, 38.8, 36.7, 33.7, 31.9, 29.62, 29.57, 29.4, 29.31, 29.33, 29.0, 28.6, 23.1, 22.7, 22.0, 14.2, 14.1; MS (FAB): m/z (%): 398 (100) $[\text{M} + \text{H}]^+$; Anal. calcd for $\text{C}_{23}\text{H}_{43}\text{NO}_4$: C, 69.48; H, 10.90; N, 3.52. Found: C, 69.34; H, 10.97; N, 3.58.

5.2.2.11. *tert*-Butyl 5-(2-oxohexadecanamido)pentanoate (8k): Yield 77%; White solid; m.p. 48-50 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.04 (t, $J = 6.2$ Hz, 1H), 3.34-3.24 (m, 2H), 2.89 (t, $J = 7.4$ Hz, 2H), 2.23 (t, $J = 6.6$ Hz, 2H), 1.65-1.48 (m, 6H), 1.43 (s, 9H), 1.23 (br s, 22H), 0.86 (t, $J = 7$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.3, 172.6, 160.1, 80.3, 38.9, 36.7, 34.8, 31.9, 29.6, 29.5, 29.4, 39.3, 29.0, 28.6, 28.0, 23.1, 22.6, 22.1, 14.1; MS (ESI): m/z (%): 448 (100) $[\text{M} + \text{Na}]^+$; Anal. calcd for $\text{C}_{25}\text{H}_{47}\text{NO}_4$: C, 70.54; H, 11.13; N, 3.29. Found: C, 70.65; H, 11.05; N, 3.21.

5.2.2.12. Ethyl 4-(2-oxohexadecanamido)benzoate (8l): Yield 84%; White solid; m.p. 86-88 °C; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 8.87 (s, 1H), 8.19-7.43 (m, 4H), 4.39 (q, $J = 7.0$ Hz, 2H), 3.02 (t, $J = 7.2$ Hz, 2H), 1.78-1.12 (m, 27H), 0.88 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.2, 165.9, 157.7, 136.5, 131.5, 129.3, 126.2, 123.9, 120.6, 61.2, 36.3, 31.9, 29.63, 29.57, 29.4, 29.34, 29.30, 29.1, 23.3, 22.7, 14.3, 14.1; MS (FAB): m/z (%): 418 (100) $[\text{M} + \text{H}]^+$; Anal. calcd for $\text{C}_{25}\text{H}_{39}\text{NO}_4$: C, 71.91; H, 9.41; N, 3.35. Found: C, 71.74; H, 9.57; N, 3.29.

5.2.2.13. (*R*)-Methyl 6-methyl-4-(2-oxohexadecanamido)heptanoate (12a): Yield 76%; Yellowish solid; m.p. 41-43 °C; $[\alpha]_{\text{D}} = -9.0$ (c 1.0, CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 6.75-6.60 (m, 1H), 4.10-3.85 (m, 1H), 3.66 (s, 3H), 2.91 (t, $J = 7.4$ Hz, 2H), 2.32 (t, $J = 7.4$ Hz, 2H), 1.95-1.40 (m, 5H), 1.40-1.18 (m, 24H), 0.95-0.81 (m, 9H). Anal. calcd for $\text{C}_{25}\text{H}_{47}\text{NO}_4$: C, 70.54; H, 11.13; N, 3.29. Found: C, 70.39; H, 11.35; N, 3.38.

5.2.2.14. (*S*)-Methyl 4-(2-oxohexadecanamido)octanoate (12b): Yield 92%; White solid; m.p. 56-58 °C; $[\alpha]_{\text{D}} = -4.6$ (c 1.0, CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 6.80-6.60 (m, 1H), 4.20-3.80 (m, 1H), 3.66 (s, 3H), 2.91 (t, $J = 7.4$ Hz, 2H), 2.35 (t, $J = 7.4$ Hz, 2H), 1.97-1.42 (m, 6H), 1.38-1.15 (m, 26H), 0.98-0.81 (m, 6H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.5, 173.6, 160.0, 51.7, 49.3, 36.8, 34.8, 31.9, 30.7, 29.9, 29.6, 29.5, 29.4, 29.3, 29.1, 27.9, 23.2, 22.7, 22.4, 14.1, 13.9. Anal. calcd for $\text{C}_{25}\text{H}_{47}\text{NO}_4$: C, 70.54; H, 11.13; N, 3.29. Found: C, 70.25; H, 11.32; N, 3.25.

5.2.2.15. (*S*)-*tert*-Butyl 4-(2-oxohexadecanamido)pentanoate (12c): Yield 95%; White solid; m.p. 52-53 °C; $[\alpha]_{\text{D}} = -1.6$ (c 1.0, CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 6.95-6.80 (m, 1H), 4.05-3.80 (m, 1H), 2.85 (t, $J = 7.4$ Hz, 2H), 2.25 (t, $J = 7.4$ Hz, 2H), 1.85-1.65 (m, 2H), 1.65-1.45 (m, 2H), 1.40 (s, 9H), 1.40-1.10 (m, 25H), 0.88 (t, $J = 6.6$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.3, 172.3, 159.6, 80.4, 45.2, 36.6, 32.1, 31.8, 31.3, 29.5, 29.4, 29.3, 29.2, 29.0, 28.0, 23.1, 22.6, 20.6, 14.0. Anal. calcd for $\text{C}_{25}\text{H}_{47}\text{NO}_4$: C, 70.54; H, 11.13; N, 3.29. Found: C, 70.38; H, 11.25; N, 3.21.

5.2.2.16. (*S*,2*E*,4*E*)-Ethyl 6-(2-oxohexadecanamido)deca-2,4-dienoate (17): Yield 91%; White solid; m.p. 53-55 °C; $[\alpha]_{\text{D}} = -11.2$ (c 0.5 CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 7.22 (dd, $J_1 = 15.2$ Hz, $J_2 = 10.8$ Hz, 1H), 6.95 (d, $J = 8.8$ Hz, 1H), 6.25 (dd, $J_1 = 15.2$ Hz, $J_2 = 10.6$ Hz, 1H), 6.00 (dd, $J_1 = 15.2$ Hz, $J_2 = 6.2$ Hz, 1H), 5.86 (d, $J = 15.8$ Hz, 1H), 4.74 (m, 1H), 4.19 (q, $J = 7.2$ Hz, 2H), 2.91 (t, $J = 7.4$ Hz, 2H), 1.73-1.44 (m, 4H), 1.28 (br s, 29H), 0.88 (m, 6H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 199.3, 166.7, 159.4, 143.3, 141.0, 128.7, 122.0, 60.3, 50.9, 36.7, 34.3, 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 27.7, 23.1, 22.6, 22.3, 14.2, 14.1, 13.9; MS (FAB):

m/z (%): 464 (37) [M + H]⁺; Anal. calcd for C₂₈H₄₉NO₄: C, 72.53; H, 10.65; N, 3.02. Found: C, 72.28; H, 10.74; N, 3.09.

5.2.2.17. (S)-Ethyl 6-(2-oxohexadecanamido)decanoate (18): Yield 93%; White solid; m.p. 47-49 °C; [α]_D = -1.6 (c 0.5 CHCl₃); ¹H NMR (200 MHz, CDCl₃) δ 6.66 (d, *J* = 9.6 Hz, 1H), 4.11 (q, *J* = 7.2 Hz, 2H), 4.00-3.81 (m, 1H), 2.92 (t, *J* = 7.4 Hz, 2H), 2.28 (t, *J* = 7.4 Hz, 2H), 1.80-1.21 (m, 39H), 0.88 (t, *J* = 6.2 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 199.7, 173.5, 159.8, 60.2, 49.4, 36.7, 34.7, 34.1, 31.9, 29.6, 29.4, 29.3, 29.1, 27.9, 25.4, 24.7, 23.2, 22.7, 22.5, 14.2, 14.1, 13.9; MS (FAB): m/z (%): 468 (87) [M + H]⁺; Anal. calcd for C₂₈H₅₃NO₄: C, 71.90; H, 11.42; N, 2.99. Found: C, 71.77; H, 11.51; N, 3.08.

5.2.2.18. (S,2E,4E)-6-(2-Oxohexadecanamido)deca-2,4-dienoic acid (19): Saponification of **15** took place before oxidation. Yield 53%; White solid; m.p. 91-93 °C; [α]_D = -35.1 (c 1 CHCl₃); ¹H NMR (200 MHz, CDCl₃) δ 7.20 (dd, *J*₁ = 15.2 Hz, *J*₂ = 10.8 Hz, 1H), 6.85 (d, *J* = 9 Hz, 1H), 6.18 (dd, *J*₁ = 15.2 Hz, *J*₂ = 11 Hz, 1H), 5.92 (dd, *J*₁ = 15.4 Hz, *J*₂ = 6.2 Hz, 1H), 5.77 (d, *J* = 15.4 Hz, 1H), 4.57-4.43 (m, 1H), 2.82 (t, *J* = 7.2 Hz, 2H), 1.76-1.43 (m, 4H), 1.14 (br s, 26H), 0.88 (m, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 199.3, 171.8, 159.5, 145.7, 142.3, 128.4, 121.0, 50.9, 36.7, 34.3, 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 27.7, 23.1, 22.6, 22.3, 14.1, 13.9; MS (FAB): m/z (%): [M + H]⁺; Anal. calcd for C₂₆H₄₅NO₄: C, 71.68; H, 10.41; N, 3.22. Found: C, 71.51; H, 10.52; N, 3.25.

5.2.2.19. 2-Oxo-N-(4-oxooctyl)hexadecanamide (26): Yield 79%; White solid; m.p. 73-76 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.09 (t, *J* = 6.4 Hz, 1H), 3.35-3.25 (m, 2H), 2.90 (t, *J* = 7.2 Hz, 2H), 2.50-2.36 (m, 4H), 1.98-1.76 (m, 2H), 1.67-1.45 (m, 4H), 1.25 (br s, 24H), 0.88 (t, *J* = 6.6 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 210.3, 199.2, 160.3, 42.6, 39.7, 38.8, 36.7, 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 25.9, 23.2, 23.1, 22.7, 22.3, 14.1, 13.8; MS (FAB): m/z (%): 396 (100) [M + H]⁺; Anal. calcd for C₂₄H₄₅NO₃: C, 72.86; H, 11.46; N, 3.54. Found: C, 72.74; H, 11.51; N, 3.59.

5.2.2.20. N-(4-Ethoxybutyl)-2-oxohexadecanamide (27): Yield 88%; White solid; m.p. 55-57 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.19 (t, *J* = 6.4 Hz, 1H), 3.52-3.25 (m, 6H), 2.90 (t, *J* = 7.8 Hz, 2H), 1.78-1.48 (m, 6H), 1.40-1.15 (m, 25H), 0.87 (t, *J* = 6.6 Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 199.4, 160.2, 69.9, 66.2, 39.0, 36.7, 31.9, 29.6, 29.5, 29.4, 29.3, 29.0, 27.1, 26.2, 23.1, 22.6, 15.1, 14.1; MS (FAB): m/z (%): 370 (100) [M + H]⁺; Anal. calcd for C₂₂H₄₃NO₃: C, 71.50; H, 11.73; N, 3.79. Found: C, 71.43; H, 11.65; N, 3.91.

5.2.2.21. Methyl 2-(2-oxo-8-phenyloctanamido)acetate (37a): Yield 82%; Oily solid; ¹H NMR (200 MHz, CDCl₃) δ 7.55-7.42 (m, 1H), 7.40-7.23 (m, 5H), 4.16 (d, *J* = 5.4 Hz, 2H), 3.86 (s, 3H), 3.00 (t, *J* = 6.8 Hz, 2H), 2.69 (t, *J* = 7.2 Hz, 2H), 1.80-1.62 (m, 4H), 1.55-1.35 (m, 4H); ¹³C NMR (50 MHz, CDCl₃) δ 198.1, 169.2, 160.2, 142.6, 128.3, 128.2, 125.6, 52.5, 40.8, 36.6, 35.8, 31.2, 28.9, 28.8, 23.0; MS (ESI) m/z(%): 328 (100) [M+Na]⁺; Anal. calcd for C₁₇H₂₃NO₄: C, 66.86; H, 7.59; N, 4.59. Found: C, 66.48; H, 7.78; N, 4.65.

5.2.2.22. tert-Butyl 3-(2-oxo-8-phenyloctanamido)propanoate (37b): Yield 83%; Oil; ¹H NMR (200 MHz, CDCl₃) δ 7.58-7.42 (m, 1H), 7.40-7.22 (m, 5H), 3.61 (q, *J* = 6.2 Hz, 2H), 2.99 (t, *J* = 7.0 Hz, 2H), 2.68 (t, *J* = 7.4 Hz, 2H), 2.56 (t, *J* = 6.2 Hz, 2H), 1.79-1.60 (m, 4H), 1.54 (s, 9H), 1.49-1.40 (m, 4H); ¹³C NMR (50 MHz, CDCl₃) δ 198.9, 171.0, 160.0, 142.6, 128.3, 128.2, 125.5, 81.3, 36.6, 35.8, 34.8, 34.7, 31.2, 28.9, 28.8, 28.0, 23.0; MS (ESI) m/z (%): 384 (100) [M+Na]⁺; Anal. calcd for C₂₁H₃₁NO₄: C, 69.78; H, 8.64; N, 3.87. Found: C, 69.40; H, 8.89; N, 3.94.

5.2.3. (*R,E*)-Ethyl 4-(*tert*-butoxycarbonyl)oct-2-enoate (39a)—To a solution of **38** (0.22g, 1.00 mmol) in a mixture of toluene-EtOAc (6 mL), a solution of NaBr (0.11 g, 1.05 mmol) in water (0.5 mL) was added, followed by AcNH-TEMPO (2.2 mg, 0.010 mmol). To the resulting biphasic system, which was cooled at $-5\text{ }^{\circ}\text{C}$, an aqueous solution of 0.35 M NaOCl (3.14 mL, 1.10 mmol) containing NaHCO_3 (0.25 g, 3 mmol) was added dropwise while stirring vigorously at $-5\text{ }^{\circ}\text{C}$ over a period of 1 h. After the mixture had been stirred for a further 15 min at $0\text{ }^{\circ}\text{C}$, EtOAc (6 mL) and H_2O (2 mL) were added. The aqueous layer was separated and washed with EtOAc (4 mL). The combined organic layers were washed consecutively with 5% aqueous citric acid (6 mL) containing KI (0.04g), 10% aqueous $\text{Na}_2\text{S}_2\text{O}_3$ (6 mL), and brine and dried over Na_2SO_4 . The solvents were evaporated under reduced pressure, and the residue was used immediately in the next step without any purification. To the solution of the *N*-protected α -amino aldehyde in dry THF (5 mL), $\text{Ph}_3\text{P}=\text{CHCOOEt}$ (1.1 mmol) was added and the reaction mixture was refluxed for 1 h. Saturated aqueous NH_4Cl (4 mL) was added and extracted with Et_2O (3×5 mL). The combined organic phases were washed with brine and dried (Na_2SO_4). The solvent was evaporated under reduced pressure, and the residue was purified by column chromatography [EtOAc-petroleum ether (bp $40\text{--}60\text{ }^{\circ}\text{C}$) 2:8]. Yield 80% (0.23g); White solid; m.p. $48\text{--}50\text{ }^{\circ}\text{C}$; $[\alpha]_{\text{D}} = +10.1$ (*c* 1, CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 6.84 (dd, $J_1 = 5.6$ Hz, $J_2 = 15.8$ Hz, 1H), 5.90 (dd, $J_1 = 1.4$ Hz, $J_2 = 15.8$ Hz, 1H), 4.52 (m, 1H), 4.38–4.05 (m, 3H), 1.80–1.10 (m, 18H), 0.89 (t, $J = 6.2$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 166.4, 155.1, 148.6, 120.5, 79.7, 60.4, 51.4, 34.3, 28.3, 27.7, 22.4, 14.2, 13.9; Anal. calcd for $\text{C}_{15}\text{H}_{27}\text{NO}_4$: C, 63.13; H, 9.54; N, 4.91. Found: C, 63.02; H, 9.69; N, 4.85.

5.2.4. General Method for Catalytic Hydrogenation—To a solution of the substrate (1.00 mmol) in MeOH (10 mL) (through which N_2 had been passed for 5 min), 10% Pd/C catalyst (10 mg, 0.01 mmol) was added. The reaction mixture was stirred under H_2 atmosphere overnight at room temperature. The catalyst was removed by filtration through a pad of Celite, and the organic solvent was evaporated under reduced pressure.

5.2.4.1. (*S*)-Ethyl 6-(*tert*-butoxycarbonylamino)decanoate (14): Yield 89%; Oil; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 4.26 (d, $J = 9.2$ Hz, 1H), 4.10 (q, $J = 7$ Hz, 2H), 3.64–3.41 (m, 1H), 2.28 (t, $J = 7.4$ Hz, 2H), 1.71–1.16 (m, 24H), 0.87 (t, $J = 6.2$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 173.7, 155.7, 78.8, 60.1, 50.4, 35.2, 34.2, 28.3, 28.0, 25.4, 24.9, 22.6, 14.2, 14.0. Anal. calcd for $\text{C}_{17}\text{H}_{33}\text{NO}_4$: C, 64.73; H, 10.54; N, 4.44. Found: C, 64.69; H, 10.61; N, 4.46.

5.2.4.2. (*R*)-Ethyl 4-(*tert*-butoxycarbonyl)octanoate (40a): Yield 99%; White solid; m.p. $32\text{--}34\text{ }^{\circ}\text{C}$; $[\alpha]_{\text{D}} = +3.4$ (*c* 1 CHCl_3); $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 4.29 (d, $J = 9.2$ Hz, 1H), 4.13 (q, $J = 6.4$ Hz, 2H), 3.62–3.45 (m, 1H), 2.36 (t, $J = 7.6$ Hz, 2H) 1.89–1.78 (m, 2H), 1.76–1.58 (m, 2H), 1.43 (s, 9H), 1.40–1.21 (m, 7H), 0.88 (t, $J = 6.4$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3) δ 173.7, 155.7, 79.0, 60.4, 50.3, 35.5, 31.1, 30.5, 28.4, 28.0, 22.5, 14.2, 14.0; Anal. calcd for $\text{C}_{15}\text{H}_{29}\text{NO}_4$: C, 62.69; H, 10.17; N, 4.87. Found: C, 62.55; H, 10.23; N, 4.95.

5.2.5. *tert*-Butyl 4-oxooctylcarbamate (22)—To a stirred solution of Boc- γ -aminobutyric acid (0.40 g, 2.0 mmol) in dry THF (2 mL), cooled at $-78\text{ }^{\circ}\text{C}$, a solution of *n*-BuLi in hexane (3 mL, 2.5M) was added dropwise. After completion of the addition, the reaction mixture was allowed to warm to room temperature and stirring was continued for 4 hours. Then, saturated NH_4Cl (5 mL) and EtOAc (10 mL) were added. The aqueous layer was separated and extracted with EtOAc (2×10 mL). The combined organic layers were dried over Na_2SO_4 , the organic solvent was evaporated under reduced pressure and the residue was purified by column-chromatography using CHCl_3 as eluent. Yield 46%; White solid; m.p. $36\text{--}38\text{ }^{\circ}\text{C}$; $^1\text{H NMR}$ (200 MHz, CDCl_3) δ 4.68 (br, 1H), 3.13–3.03 (m, 2H), 2.45–2.33 (m, 4H), 1.87–1.65 (m, 2H), 1.55–1.23 (m, 13H), 0.86 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C NMR}$ (50 MHz, CDCl_3)

δ 210.7, 156.0, 79.0, 42.5, 40.0, 39.7, 28.3, 25.8, 23.9, 22.2, 13.7. Anal. calcd for $C_{13}H_{25}NO_3$: C, 64.16; H, 10.36; N, 5.76. Found: C, 64.10; H, 10.42; N, 5.71.

5.2.6. *tert*-Butyl 4-ethoxybutylcarbamate (23)—To a stirred solution of *tert*-butyl 4-hydroxybutylcarbamate (0.38 g, 2.0 mmol) and ethyl bromide (0.65 g, 6 mmol) in benzene (2 mL) at 10 °C, aq. 50% NaOH (2 mL) and phase transfer catalyst Bu_4NHSO_4 (0.08 g, 0.3 mmol) were added. The reaction mixture was vigorously stirred for 4 h at 10 °C and overnight at room temperature. The aqueous layer was separated and extracted with EtOAc (2×5 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 . The organic solvent was evaporated under reduced pressure and the residue was purified by column-chromatography using $CHCl_3$ as eluent. Yield 95%; Oil; 1H NMR (200 MHz, $CDCl_3$) δ 4.72 (br, 1H), 3.46-3.34 (m, 4H), 3.19-3.06 (m, 2H), 1.60-1.43 (m, 4H), 1.38 (s, 9H), 1.14 (t, J = 7.4 Hz, 3H); ^{13}C NMR (50 MHz, $CDCl_3$) δ 155.9, 78.7, 70.1, 66.0, 40.3, 28.3, 27.0, 26.8, 15.0. Anal. calcd for $C_{11}H_{23}NO_3$: C, 60.80; H, 10.67; N, 6.45. Found: C, 60.55; H, 10.81; N, 6.32.

5.2.7. 2-Hydroxy-8-phenyloctanenitrile (34)—To a stirred solution of **33** (0.45 g, 2.4 mmol) in CH_2Cl_2 (3 mL), a solution of $NaHSO_3$ (0.37 g, 3.5 mmol) in water (0.6 mL) was added and the mixture was vigorously stirred for 30 min at room temperature. The organic solvent was evaporated under reduced pressure, water was added and the mixture was cooled at 0 °C. Then, a solution of KCN (0.23 g, 3.5 mmol) in water (0.6 mL) was added drop-wise over a period of 3.5 h and then the mixture was left under stirring overnight at room temperature. The aqueous suspension was extracted with CH_2Cl_2 (2×5 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 . The solvent was evaporated under reduced pressure and the residue was purified by column-chromatography using $CHCl_3$ as eluent. Yield 75%; Oil; 1H NMR (200 MHz, $CDCl_3$) δ 7.40-7.22 (m, 5H), 4.58-4.35 (m, 1H), 3.90-3.78 (m, 1H), 2.69 (t, J = 6.6 Hz, 2H), 1.95-1.80 (m, 2H), 1.80-1.60 (m, 2H), 1.60-1.40 (m, 6H); ^{13}C NMR (50 MHz, $CDCl_3$) δ 142.4, 128.2, 128.1, 125.5, 120.0, 60.9, 35.7, 34.8, 31.1, 28.8, 28.6, 24.3; Anal. calcd for $C_{14}H_{19}NO$: C, 77.38; H, 8.81; N, 6.45. Found: C, 77.11; H, 8.95; N, 6.37.

5.2.8. 2-Hydroxy-8-phenyloctanoic acid (35)—A solution of **34** (0.36 g, 1.7 mmol) in conc. HCl (4.2 mL) was stirred overnight at room temperature. Then, water was added and the aqueous solution was extracted with $CHCl_3$ (3×5 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 . The organic solvent was evaporated under reduced pressure and the resulting 2-hydroxy-8-phenyloctanamide was precipitated using Et_2O .

To a solution of 2-hydroxy-8-phenyloctanamide (0.32 g, 1.3 mmol) in a mixture of EtOH/water (2:1, 10 mL), KOH (0.75 g, 13.4 mmol) was added and the reaction mixture was refluxed for 4 h. After cooling, EtOH was removed under reduced pressure, water was added and the aqueous solution was acidified with conc. H_2SO_4 until pH 1, followed by extraction with Et_2O (3×5 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 . The organic solvent was evaporated under reduced pressure and the residue was purified by recrystallization using CH_2Cl_2 /petroleum ether. Yield 85%; White solid; m.p. 84-86 °C; 1H NMR (200 MHz, $CDCl_3$) δ 7.35-7.24 (m, 5H), 4.40-4.25 (m, 1H), 2.68 (t, J = 6.6 Hz, 2H), 2.00-1.82 (m, 2H), 1.80-1.58 (m, 3H), 1.58-1.15 (m, 6H); ^{13}C NMR (50 MHz, $CDCl_3$) δ 179.5, 142.6, 128.4, 128.2, 125.6, 70.2, 35.9, 34.1, 29.0, 24.6; Anal. calcd for $C_{14}H_{20}O_3$: C, 71.16; H, 8.53. Found: C, 70.92; H, 8.84.

5.2.9. (R)-4-(7-Phenylheptanamido)octanoic acid (42)—To a stirred solution of **41a** (or **41b**) (2.00 mmol) in a mixture of dioxane/ H_2O (9:1, 20 mL), 1N NaOH (2.2 mL, 2.2 mmol) was added, and the mixture was stirred for 12 h at room temperature. The organic solvent was evaporated under reduced pressure, and H_2O (10 mL) was added. The aqueous layer was washed with EtOAc, acidified with 1N HCl, and extracted with EtOAc (3×12 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and evaporated under

reduced pressure. The residue was purified after recrystallization [EtOAc/petroleum ether (bp 40-60 °C)]. Yield 90%; White solid; m.p. 73-75 °C; $[\alpha]_D = -5.7$ (c 1 CHCl₃); ¹H NMR (200 MHz, CDCl₃) δ 11.10 (br s, 1H), 7.39-7.23 (m, 5H), 5.86 (d, $J = 9.0$ Hz, 1H), 4.10-3.94 (m, 1H), 2.68 (t, $J = 7.4$ Hz, 2H), 2.46 (t, $J = 7.4$ Hz, 2H), 2.26 (t, $J = 7.4$ Hz, 2H), 2.04-1.87 (m, 1H), 1.82-1.57 (m, 5H), 1.57-1.09 (m, 10H), 0.97 (t, $J = 6.4$ Hz, 3H); ¹³C NMR (50 MHz, CDCl₃) δ 177.4, 173.9, 142.5, 128.3, 128.1, 125.5, 49.0, 36.6, 35.8, 34.9, 31.2, 31.1, 30.2, 29.0, 28.8, 28.0, 25.7, 22.4, 13.9; MS (ESI) m/z (%): 370 (100) [M+Na]⁺; Anal. calcd for C₂₁H₃₃NO₃: C, 72.58; H, 9.57; N, 4.03. Found: C, 72.26; H, 9.74; N, 4.11.

Compounds **10a-c**,²⁶ **13**,³⁰ **29**,⁴⁹ **30**,⁵⁰ **31**,³⁵ **33**,⁵¹ **38**,⁵² **39b**,²⁶ **40b**²⁶ have been described previously.

5.3. In-vitro PLA₂ Assays

Phospholipase A₂ activity was determined using the previously described modified Dole assay²⁵ with buffer and substrate conditions optimized for each enzyme as described previously:^{25,26,29,30} (i) GIVA cPLA₂ substrate mixed-micelles were composed of 400 μ M Triton X-100, 97 μ M PAPC, 1.8 μ M ¹⁴C-labeled PAPC, and 3 μ M PIP₂ in buffer containing 100 mM HEPES pH 7.5, 90 μ M CaCl₂, 2 mM DTT and 0.1 mg/ml BSA; (ii) GVI iPLA₂ substrate mixed-micelles were composed of 400 μ M Triton X-100, 99 μ M DPPC, and 1.5 μ M ¹⁴C-labeled DPPC in buffer containing 200 mM HEPES pH 7.0, 1 mM ATP, 2 mM DTT and 0.1 mg/ml BSA; and (iii) GV sPLA₂ substrate mixed-micelles were composed of 400 μ M Triton X-100, 99 μ M DPPC, and 1.5 μ M ¹⁴C-labeled DPPC in buffer containing 50 mM Tris pH 8.0 and 5 mM CaCl₂.

5.4. In-vitro PLA₂ Inhibition Studies

Initial screening of compounds at 0.091 mole fraction inhibitor in mixed-micelles was carried out. We considered compounds displaying 25% or less inhibition to have no inhibitory effect (designated N.D.). We report average percent inhibition (and standard error, n=3) for compounds displaying more than 25% and less than 90% enzyme inhibition. If percent inhibition was greater than 90%, we determined its X_I(50) by plotting percent inhibition vs. inhibitor molar fraction (7 points; typically 0.005 to 0.091 mole fraction). Inhibition curves were modeled in Graphpad Prism using either a linear (x, y intercept = 0) or non-linear regression (one-site binding model - hyperbola, BMAX = 100) to calculate the reported X_I(50) and associated error values.

Acknowledgments


The project is co-funded by the European Social Fund and National Resources (EPEAEK II) (G.K.) and by NIH Grant GM 20,501 (E.A.D.).

References and notes

- Schaloske RH, Dennis EA. *Biochim. Biophys. Acta* 2006;1761:1246–1259. [PubMed: 16973413]
- Balsinde J, Winstead MV, Dennis EA. *FEBS Lett* 2002;531:2–6. [PubMed: 12401193]
- Six DA, Dennis EA. *Biochim. Biophys. Acta* 2000;1488:1–19. [PubMed: 11080672]
- Kudo I, Murakami M. *Prostag. Oth. Lipid M* 2002;68-69:3–58.
- Leslie CC. *Prostaglandins Leukot. Essent. Fatty Acids* 2004;70:373–376. [PubMed: 15041029]
- Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. *Nature* 1997;390:622–625. [PubMed: 9403693]
- Uozumi N, Kume K, Nagase T, Nakatani N, Ishii S, Tashiro F, Komagata Y, Maki K, Ikuta K, Ouchi Y, Miyazaki J, Shimizu T. *Nature* 1997;390:618–622. [PubMed: 9403692]
- Kalyvas A, David S. *Neuron* 2004;41:323–335. [PubMed: 14766173]

9. Marusic S, Leach MW, Pelker JW, Azoitei ML, Uozumi N, Cui JQ, Shen MWH, DeClercq CM, Miyashiro JS, Carito BA, Thakker P, Simmons DL, Leonard JP, Shimizu T, Clark JD. *J. Exp. Med* 2005;202:841–851. [PubMed: 16172261]
10. For reviews see: (a) Winstead MV, Balsinde J, Dennis EA. *Biochim. Biophys. Acta* 2000;1488:28–39. [PubMed: 11080674] (b) Balsinde J, Balboa MA. *Cellular Signalling* 2005;17:1052–1062. [PubMed: 15993747]
11. Satake Y, Diaz BL, Balestrieri B, Lam BK, Kanaoka Y, Grusby MJ, Arm JP. *J. Biol. Chem* 2004;279:16488–16494. [PubMed: 14761945]
12. Mounier CM, Ghomashchi F, Lindsay MR, James S, Singer AG, Parton RG, Gelb MH. *J. Biol. Chem* 2004;279:25024–25038. [PubMed: 15007070]
13. Kuwata H, Nonaka T, Murakami M, Kudo I. *J. Biol. Chem* 2005;280:25830–25839. [PubMed: 15878884]
14. Shirai Y, Balsinde J, Dennis EA. *Biochim. Biophys. Acta* 2005;1735:119–129. [PubMed: 15967714]
15. Ni Z, Okeley NM, Smart BP, Gelb MH. *J. Biol. Chem* 2006;281:16245–16255. [PubMed: 16603549]
16. Chen J, Engle SJ, Seilhamer JJ, Tischfield JA. *J. Biol. Chem* 1994;269:2365–2368. [PubMed: 8300559]
17. Chen Y, Dennis EA. *Biochim. Biophys. Acta* 1998;1394:57–64. [PubMed: 9767110]
18. Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tischfield JA, Kudo I. *J. Biol. Chem* 1998;273:14411–14423. [PubMed: 9603953]
19. For recent reviews see: (a) Balestrieri B, Arm JP. *Biochim. Biophys. Acta* 2006;1761:1280–1288. [PubMed: 16945583] (b) Rosengren B, Jonsson-Rylander A-C, Peilot H, Camejo G, Hurt-Camejo E. *Biochim. Biophys. Acta* 2006;1761:1301–1308. [PubMed: 17070102]
20. Magrioti V, Kokotos G. *Anti-Inflamm. Anti-Allergy Agents Med. Chem* 2006;5:189–203.
21. McKew JC, Foley MA, Thakker P, Behnke ML, Lovering FE, Sum F-W, Tam S, Wu K, Shem MWH, Zhang W, Gonzalez M, Liu S, Mahadevan A, Sard H. *J. Med. Chem* 2006;49:135–158. [PubMed: 16392799]
22. Lee KL, Foley MA, Chen LR, Behnke ML, Lovering FE, Kirincich SJ, Wang WH, Shim J, Tam S, Shen MWH, Khor SP, Xu X, Goodwin DG, Ramarao MK, Nickerson-Nutter C, Donahue F, Ku MS, Clark JD, McKew JC. *J. Med. Chem* 2007;50:1380–1400. [PubMed: 17305324]
23. Lee KL, Behnke ML, Foley MA, Chen L, Wang W, Vargas R, Nunez J, Tam S, Mollova N, Xu X, Shen MWH, Ramarao MK, Goodwin DG, Nickerson-Nutter CL, Abraham WM, Williams C, Clark JD, McKew JC. *Bioorg. Med. Chem* 2008;16:1345–1358. [PubMed: 17998165]
24. Ludwig J, Bovens S, Brauch C, Elfringhoff AS, Lehr M. *J. Med. Chem* 2006;49:2611–2620. [PubMed: 16610804]
25. Kokotos G, Kotsovolou S, Six DA, Constantinou-Kokotou V, Beltzner CC, Dennis EA. *J. Med. Chem* 2002;45:2891–2893. [PubMed: 12086476]
26. Kokotos G, Six DA, Loukas V, Smith T, Constantinou-Kokotou V, Hadjipavlou-Litina D, Kotsovolou S, Chiou A, Beltzner CC, Dennis EA. *J. Med. Chem* 2004;47:3615–3628. [PubMed: 15214789]
27. Constantinou-Kokotou V, Peristeraki A, Kokotos CG, Six DA, Dennis EA. *J. Pept. Sci* 2005;11:431–435. [PubMed: 15635664]
28. Yaksh TL, Kokotos G, Svensson CI, Stephens D, Kokotos CG, Fitzsimmons B, Hadjipavlou-Litina D, Hua X-Y, Dennis EA. *J. Pharmacol. Exp. Ther* 2006;316:466–475. [PubMed: 16203828]
29. Stephens D, Barbayianni E, Constantinou-Kokotou V, Peristeraki A, Six DA, Cooper J, Harkewicz R, Deems RA, Dennis EA, Kokotos G. *J. Med. Chem* 2006;49:2821–2828. [PubMed: 16640343]
30. Six DA, Barbayianni E, Loukas V, Constantinou-Kokotou V, Hadjipavlou-Litina D, Stephens D, Wong AC, Magrioti V, Moutevelis-Minakakis P, Baker S, Dennis EA, Kokotos G. *J. Med. Chem* 2007;50:4222–4235. [PubMed: 17672443]
31. Moutevelis-Minakakis P, Neokosmida A, Filippakou M, Stephens D, Dennis EA, Kokotos G. *J. Pept. Sci* 2007;13:634–641. [PubMed: 17631670]
32. Antonopoulou G, Magrioti V, Stephens D, Constantinou-Kokotou V, Dennis EA, Kokotos G. *J. Pept. Sci.* 2008 in press.
33. Reid RC. *Curr. Med. Chem* 2005;12:3011–3026. [PubMed: 16378502]

34. Beaton HG, Bennion C, Connolly S, Cook AR, Gensmantel NP, Hallam C, Hardy K, Hitchin B, Jackson CG, Robinson DH. *J. Med. Chem* 1994;37:557–559. [PubMed: 8126692]
35. Hansford KA, Reid RC, Clark CI, Tyndall JDA, Whitehouse MW, Guthrie T, McGeary RP, Schafer K, Martin JL, Fairlie DP. *ChemBioChem* 2003;4:181–185. [PubMed: 12616631]
36. Arumugam TV, Arnold N, Proctor LM, Newman M, Reid RC, Hansford KA, Fairlie DP, Shiels IA, Taylor SM. *Br. J. Pharmacol* 2003;140:71–80. [PubMed: 12967936]
37. Woodruff TM, Arumugam TV, Shiels IA, Newman ML, Ross PA, Reid RC, Fairlie DP, Taylor SM. *Intern. Immunopharm* 2005;5:883–892.
38. Dess DB, Martin JC. *J. Am. Chem. Soc* 1991;113:7277–7287.
39. Ma Z, Bobbitt JM. *J. Org. Chem* 1991;56:6110–6114.
40. Leanna MR, Sowin TJ, Morton HE. *Tetrahedron Lett* 1992;33:5029–5032.
41. Takacs JM, Jaber MR, Clement F, Walters C. *J. Org. Chem* 1998;63:6757–6760.
42. Kokotos G. *Synthesis* 1990:299–301.
43. Kokotos G, Noula C. *J. Org. Chem* 1996;61:6994–6996. [PubMed: 11667598]
44. Chiou A, Markidis T, Constantinou-Kokotou V, Verger R, Kokotos G. *Org. Lett* 2000;2:347–350. [PubMed: 10814319]
45. Kokotos G, Verger R, Chiou A. *Chem. Eur. J* 2000;6:4211–4217.
46. Chiou A, Verger R, Kokotos G. *Lipids* 2001;36:535–542. [PubMed: 11432468]
47. Kotsovolou S, Chiou A, Verger R, Kokotos G. *J. Org. Chem* 2001;66:962–967. [PubMed: 11430119]
48. Kokotos G. *J. Mol. Catal. B-Enzym* 2003;22:255–269.
49. Fawzi MM, Gutsche CD. *J. Org. Chem* 1966;31:1390–1393.
50. Hadei N, Assen BE, Kantchen B, O' Brien CJ, Organ MG. *J. Org. Chem* 2005;70:8503–8507. [PubMed: 16209599]
51. Spencer TA, Onofrey TJ, Cann RO, Russel JS, Lee LE, Blanchard DE, Castro A, Gu P, Jiang G, Shechter J. *J. Org. Chem* 1999;64:807–818. [PubMed: 11674151]
52. Kokotos G, Constantinou-Kokotou V, Noula C, Nicolaou A, Gibbons WA. *Int. J. Pept. Protein Res* 1996;48:160–166. [PubMed: 8872534]



1a, $R^1 = H$, $R^2 = H$, $n = 1$

1b, $R^1 = (CH_2)_2CH_3$, $R^2 = H$, $n = 1$

1c, $R^1 = (CH_2)_2CH_3$, $R^2 = H$, $n = 2$

1d, $R^1 = H$, $R^2 = Et$, $n = 1$ (AX048)






Figure 1.
Amino acid-based inhibitors of phospholipase A_2 enzymes.






Figure 2. Inhibition curve for amide **42** in a mixed-micelle assay with human GV sPLA₂. Non-linear regression (hyperbolic) estimated a $X_I(50)$ value of 0.003 ± 0.0004 . Compound **42** did not inhibit GIVA cPLA₂ and GVIA iPLA₂ at 0.091 mole fraction.

**Scheme 1. Reagents and conditions**


(a) CH₃(CH₂)₁₃CH(OH)COOH, WSCI, HOBT, Et₃N, CH₂Cl₂; (b) Dess-Martin periodinane, CH₂Cl₂.




9-12	R ¹	R ²	P
a	i-Bu	Me	Boc
b	n-Bu	Me	Boc
c	Me	Bu ^t	Z

Scheme 2. Reagents and conditions


(a) i. NaOCl, TEMPO, NaBr, NaHCO₃, EtOAc/PhCH₃/H₂O 3:3:0.5, -5 °C; ii. Ph₃P=CHCOOR², THF, reflux; (b) H₂, 10% Pd/C, EtOH; (c) 4 N HCl/Et₂O; (d) CH₃(CH₂)₁₃CH(OH)COOH, WSCI, HOBT, Et₃N, CH₂Cl₂; (e) Dess-Martin periodinane, CH₂Cl₂.

**Scheme 3. Reagents and conditions**


(a) NaOCl, TEMPO, NaBr, NaHCO₃, EtOAc/PhCH₃/H₂O 3:3:0.5, -5 °C; (b) (EtO)₂P(=O)CH₂CH=CHCOOEt, LiOH, PhCH₃, r.t.; (c) H₂, 10% Pd/C, EtOH; (d) i. 4 N HCl/Et₂O; ii. CH₃(CH₂)₁₃CHOHCOOH, WSCI, HOBT, Et₃N, CH₂Cl₂; (e) Dess-Martin periodinane, CH₂Cl₂; (f) 1 N NaOH, CH₃OH.

**Scheme 4. Reagents and conditions**

(a) i. NMM, ClCO₂Et, THF; ii. NaBH₄, MeOH; (b) n-BuLi/hexane, THF; (c) i. 4 N HCl/Et₂O; ii. CH₃(CH₂)₁₃CHOHCOOH, WSCI, HOBt, Et₃N, CH₂Cl₂; (d) Dess-Martin periodinane, CH₂Cl₂; (e) EtBr, Bu₄NHSO₄, 50% NaOH, C₆H₆.

**Scheme 5. Reagents and conditions**

(a) $\text{Br}^- \text{Ph}_3\text{P}^+(\text{CH}_2)_5\text{COOEt}$, NaH, THF; (b) H_2 , 10% Pd/C, EtOH; (c) 1 N NaOH, dioxane; (d) $\text{H}_2\text{N}(\text{CH}_2)_n\text{COOR}$, WSCI, HOBT, Et_3N , CH_2Cl_2 ; (e) DIBALH, dry Et_2O ; (f) NaOCl, TEMPO, NaBr, NaHCO_3 , $\text{EtOAc}/\text{PhCH}_3/\text{H}_2\text{O}$ 3:3:0.5, -5°C ; (g) NaHSO_3 , KCN, H_2O , CH_2Cl_2 ; (h) conc. HCl; (i) KOH, $\text{EtOH}/\text{H}_2\text{O}$; (j) Dess-Martin periodinane, CH_2Cl_2 .

**Scheme 6. Reagents and conditions**

(a) NaOCl, TEMPO, NaBr, NaHCO₃, EtOAc/PhCH₃/H₂O 3:3:0.5, -5 °C; (b) Ph₃P=CHCOOMe, THF, reflux; (c) H₂, 10% Pd/C, MeOH; (d) 4 N HCl/Et₂O, (e) Ph(CH₂)₆COOH, WSCI, HOBT, Et₃N, CH₂Cl₂; (f) 1 N NaOH, dioxane.

Table 1

Inhibition of PLA₂ by 2-oxoamide esters. Average percent inhibition and standard error (n=3) reported for each compound at 0.091 mole fraction. N.D. signifies compounds with less than 25% inhibition (or no detectable inhibition).

Entry	Structure
8a	
8b	
8c	
8d	
8e	
8f	
8g	
8h	







Entry	Structure
8i	
8j	
8k	

Table 2

Inhibition of PLA2 by 2-oxoamides based on esters of γ - and ϵ -amino acids and related compounds. Average percent inhibition and standard error (n=3) reported for each compound at 0.091 mole fraction. N.D. signifies compounds with less than 25% inhibition (or no detectable inhibition).

Entry	Structure
12a	
12b	
12c	

Entry	Structure
17	
18	
19	





Entry	Structure
81	
26	
27	

Table 3

Inhibition of PLA₂ by 2-oxoamide and amide containing 7-phenylheptanoyl chain. Average percent inhibition and standard error (n=3) reported for each compound at 0.091 mole fraction. N.D. signifies compounds with less than 25% inhibition (or no detectable inhibition).

Entry	Structure
37a	
37b	
32a	
32b	
42	

Entry	Structure
43	 <p>The chemical structure shows a proline ring (a five-membered ring with one nitrogen atom) attached to a heptanoyl chain. The heptanoyl chain is further substituted with a phenyl group at the 7-position. The proline ring is shown in a chair-like conformation with the nitrogen atom bonded to a hydrogen atom. The heptanoyl chain is attached to the nitrogen atom of the proline ring. The phenyl group is attached to the end of the heptanoyl chain. The structure is drawn in a skeletal format with a dashed bond for the hydrogen on the nitrogen atom and a solid wedge for the bond to the heptanoyl chain.</p>